Hepatic Safety of Eviplera(R) in HIV/Hepatitis C (HCV)-Coinfected Patients Without HCV Treatment in the "The HEPAVIR HEPATIC SAFETY Cohort." hEPAtic Study.
Phase of Trial: Phase IV
Latest Information Update: 20 Oct 2016
Price : $35 *
At a glance
- Drugs Emtricitabine/rilpivirine/tenofovir disoproxil fumarate (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- Acronyms hEPAtic Study
- 31 Aug 2018 Biomarkers information updated
- 04 Aug 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 30 Apr 2015 Planned End Date changed from 1 Dec 2014 to 1 Jul 2015 as reported by ClinicalTrials.gov record.